EVE Health Group Limited (EVE) AI Stock Analysis

• Market Cap: AU$5.70M
• Dividend Yield: N/A
• Average Volume (3M): 774.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.22
• Revenue Growth: -18.70%
• EPS Growth: 20.83%
• Country: AU
• Employees: 3
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): >-0.01
• Shares Outstanding: 284,876,600
• 10 Day Avg. Volume: 491,958
• 30 Day Avg. Volume: 774,070
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.22
• Price to Sales (P/S): 2.49
• P/FCF Ratio: -2.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.02 ▼(-10.00% Downside)
• Action: Reiterated Date: 11/18/25
• Date: Action: Reiterated 11/18/25

EVE Health Group Limited's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability issues. Technical analysis indicates bearish trends, and valuation metrics are unattractive due to negative earnings. The absence of earnings call insights and corporate events further limits the score.

Positive Factors

Low leverage / conservative capital structure

A very low debt-to-equity ratio indicates the company carries minimal financial leverage, reducing refinancing and interest-rate risk. This conservative capital structure provides durability through economic cycles, preserving flexibility to fund operations or strategic moves over the next several months.

Improving free cash flow

Improving free cash flow growth, together with a free cash flow to net income ratio reported as stable at 1.0, signals better cash generation discipline. Sustained FCF improvement supports internal funding for working capital or small investments and reduces near-term financing reliance.

Gross margin improvement

Rising gross margins suggest progress on product mix, pricing or input-cost control. If sustained, higher gross margins improve the headroom to cover fixed costs and are a prerequisite for restoring operating profitability as revenue stabilizes or grows over the medium term.

Negative Factors

Declining revenue

Material year-over-year revenue decline erodes scale and makes profitable cost absorption harder. Persistent top-line weakness undermines long-term growth prospects, limits operating leverage benefits, and requires either renewed demand or successful new initiatives to reverse the trend.

Negative operating cash flow

Negative operating cash flow indicates the company is not converting its activities into sustainable cash, forcing reliance on external funding or asset sales. Over months this constrains reinvestment, limits the ability to scale, and increases liquidity and execution risk.

Persistent negative profitability / negative ROE

A negative ROE shows the business is destroying shareholder capital rather than creating it. Sustained negative profitability weakens the balance sheet, deters investment, and suggests structural issues in the business model or cost base that must be addressed for long-term viability.

EVE Health Group Limited Business Overview & Revenue Model

Company Description

Eve Health Group Limited, together with its subsidiaries, engages in the production and distribution of nutrition, health, and wellness products in Australia, New Zealand, the Asia Pacific, and North America. It provides organic tea tree oils; and distributes botanical oils, as well as supplies essential oils, hydrosols, extracts, carrier oils, and seed oils. The company also offers organic raw honey and raw honey probiotic concentrates; and contract manufacturing services. In addition, it offers medical nutrition solutions for chronic and lifestyle diseases, including Gluco Smooth for type 2 diabetes that reduces the post-meal blood sugar levels; and dietary interventions. The company was formerly known as EVE Investments Limited. Eve Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.

How the Company Makes Money

EVE Health Group Limited generates revenue through multiple streams, primarily by offering subscription-based telehealth services, which provide users with access to healthcare professionals and resources. Additionally, the company earns income from the sale of medical devices tailored for women's health, as well as licensing agreements for its proprietary health information platforms. Strategic partnerships with healthcare providers and organizations further enhance EVE's market reach and contribute to its financial stability, allowing the company to tap into broader networks and customer bases.

EVE Health Group Limited Financial Statement Overview

Summary

EVE Health Group Limited faces significant financial challenges, with declining revenues and persistent profitability issues. Despite a low leverage position, the company struggles to generate returns on equity. Cash flow improvements are noted, but operational cash flow difficulties persist.

Income Statement

EVE Health Group Limited has experienced declining revenue growth, with a notable decrease of 13.44% in the latest year. The company has consistently reported negative net profit margins, indicating ongoing profitability challenges. Gross profit margins have shown some improvement, but EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio is low at 0.03, suggesting limited leverage and a conservative capital structure. However, the return on equity is negative, indicating that the company is not generating returns on shareholders' equity. The equity ratio is relatively stable, showing a solid equity base compared to total assets.

Cash Flow

EVE Health Group Limited has shown improvement in free cash flow growth, but operating cash flow remains negative, indicating cash flow challenges. The operating cash flow to net income ratio is negative, suggesting that the company is not effectively converting its net income into cash flow. The free cash flow to net income ratio is stable at 1.0, indicating that free cash flow aligns with net income.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	1.36M	1.73M	2.13M	2.33M	2.01M	2.80M
Gross Profit	385.07K	824.03K	876.96K	827.83K	-1.00M	-713.50K
EBITDA	-1.65M	-1.43M	-1.51M	-2.18M	-4.53M	-2.79M
Net Income	-1.62M	-1.58M	-1.90M	-4.04M	-5.37M	-3.63M
Balance Sheet
Total Assets	4.07M	4.12M	2.52M	4.13M	8.07M	11.92M
Cash, Cash Equivalents and Short-Term Investments	929.66K	903.42K	106.17K	192.48K	1.10M	3.16M
Total Debt	38.51K	91.28K	74.85K	4.28K	492.39K	1.01M
Total Liabilities	307.63K	572.45K	1.30M	1.01M	1.14M	1.74M
Stockholders Equity	3.76M	3.55M	1.22M	3.12M	6.93M	10.19M
Cash Flow
Free Cash Flow	-1.54M	-1.62M	-1.11M	-1.65M	-3.80M	-2.51M
Operating Cash Flow	-1.54M	-1.62M	-1.11M	-1.65M	-3.77M	-2.24M
Investing Cash Flow	302.79K	2.13M	874.27K	498.46K	-26.05K	-263.38K
Financing Cash Flow	1.78M	279.09K	146.37K	240.69K	1.74M	529.43K

EVE Health Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
NGS	43 Neutral	AU$6.66M	-0.26	―	―	-21.84%	79.99%
OMG	42 Neutral	AU$8.52M	-4.69	-77.48%	―	63.30%	70.00%
EVE	41 Neutral	AU$5.70M	-1.62	-60.84%	―	-18.70%	20.83%
HCT	41 Neutral	AU$25.75M	-33.08	―	―	6.76%	―
CCO	37 Underperform	AU$9.18M	-1.73	-555.97%	―	88.48%	51.61%

EVE Health Group Limited Corporate Events

EVE Health bolsters scientific board as Libbo erectile dysfunction treatment rolls out

EVE Health Group has appointed specialist sexual health physician and general practitioner Dr Sama Balasubramanian to its Scientific Advisory Board, adding deep expertise in men’s health, sexual medicine, medical education and health governance to its advisory ranks. His background includes leadership roles in professional training and policy, as well as experience in evaluating and developing therapeutics for erectile dysfunction and related conditions.

The appointment comes as EVE rolls out Libbo, its oral dissolving film treatment for erectile dysfunction, and advances a broader sexual and reproductive health pipeline supported by a digital prescribing and fulfilment platform. Management expects the strengthened Scientific Advisory Board to enhance product development, clinical trial design and standards-of-care alignment, potentially supporting the commercial uptake of Libbo and positioning EVE more strongly in large, underserved markets for sexual health therapies.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health launches erectile dysfunction drug Libbo and integrated men’s digital health platform

EVE Health Group has launched Libbo, its oral dissolving film treatment for erectile dysfunction, in Australia and activated a dedicated men’s health digital platform, stiffissue.com. The company has partnered with telehealth providers hubMed and TeleDocs Clinic and delivery service Chemist2U to create an end-to-end digital pathway for assessment, prescription and home delivery.

The integrated model marks EVE’s transition from pure manufacturing and distribution into real-world patient access, underpinning scalable national reach and near-term revenue generation in men’s health. By combining proprietary products with digital engagement and clinical networks, EVE aims to reduce stigma and access barriers for erectile dysfunction, strengthen its vertically integrated commercial model and lay the groundwork for expansion into additional therapeutic indications.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Moves Into Commercial Phase With First Dyspro Prescriptions and Libbo Manufacturing Milestone

EVE Health Group has transitioned from development to early commercialisation in the December 2025 quarter, with first patient prescriptions of Dyspro™ under Australian regulatory pathways and completion of the initial commercial manufacturing run of Libbo™, which is now in national distribution and positioned for near-term prescribing via telehealth and pharmacies. The company strengthened its clinical and patient engagement infrastructure through a national telehealth patient support agreement with hubMed, launch of the Reclaim My Cycle education and research platform for women with period pain, appointment of its first Medical Science Liaison to drive prescriber education, and a $1.1 million capital raising to accelerate the rollout and regulatory progression of both flagship products, leaving it with $0.9 million in cash and signaling growing investor confidence in its commercialisation strategy.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Group Finalises First Commercial Production of Libbo Erectile Dysfunction Treatment

EVE Health Group has completed the first commercial manufacturing run of Libbo, its oral dissolving film treatment for erectile dysfunction, and delivered inventory to a national distribution partner, moving the product from development into commercial launch. With quality-assured stock now integrated into national warehousing, logistics and fulfilment systems, and telehealth prescribing and pharmacy channels in place, the company is positioned for imminent market entry, advancing its men’s health portfolio and underpinning its broader strategy to build scalable, revenue-generating pharmaceutical offerings in the sizable and growing erectile dysfunction treatment market.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.

EVE Health Director Stuart Gunzburg Increases Stake with On‑Market Share Purchase

EVE Health Group Limited has disclosed a change in the shareholding of director Stuart Gunzburg, who acquired 200,000 ordinary shares in the company on 2 January 2026 via an on‑market trade for a total consideration of A$4,200. Following the transaction, Gunzburg’s direct holding remains at 7,936,508 ordinary shares, while his indirect interests through various associated entities increased to 1,180,555 ordinary shares and 1,000,000 unlisted options, signalling a modest increase in his overall equity exposure and aligning his interests more closely with shareholders, though without indicating any broader strategic shift at the company.

The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.